☆ 4.6 Review

The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma

FRONTIERS IN ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/beta-catenin signaling

Huajian Yu et al.

Summary: This study aims to identify molecular factors specific to CD133(+) HCC and discover their role in cancer stemness. Transcriptome profiling revealed the overexpression of SERPINA12 in HCC CD133(+) cells, which is associated with aggressive clinical features and stemness signatures. Functional characterization showed that SERPINA12 promotes self-renewal, therapy resistance, and metastasis by activating the AKT/beta-catenin signaling cascade through binding to GRP78.

HEPATOLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Enhanced mitophagy driven by ADAR1-GLI1 editing supports the self-renewal of cancer stem cells in hepatocellular carcinoma

Jie Luo et al.

Summary: This study reveals that ADAR1 regulates the properties of liver cancer stem cells (LCSCs) by editing GLI1 gene. Overediting of GLI1 induces an R701G substitution, enhancing tumor-initiating potential and aggressiveness. GLI1R701G promotes LCSC self-renewal through increased pluripotency gene expression. Additionally, ADAR1-enriched LCSCs show hyperactivated mitophagy, and GLI1 editing promotes a metabolic switch to control stress and stem-like state.

HEPATOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Cellular and Molecular Biology of Cancer Stem Cells of Hepatocellular Carcinoma

Kuo-Shyang Jeng et al.

Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide. Cancer stem cells (CSCs) in HCC play essential roles in tumor progression, resistance to therapy, and metastasis. Several surface markers, including EpCAM, CD90, CD44, and CD133, are used to identify liver CSCs, and multiple molecular signaling pathways, such as Wnt/beta-catenin, TGF-beta, SHH, PI3K/Akt/mTOR, and Notch, are implicated. Different markers are associated with poor prognosis, advanced tumor stages, early metastasis, and increased recurrence rate. Targeting CSCs and reducing their population is crucial for improving the treatment of advanced HCC.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Oncology

Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib

Jung Woo Eun et al.

Summary: This study discovered that cancer-associated fibroblasts (CAFs) play a crucial role in inducing resistance to tyrosine kinase inhibitors (TKIs) in hepatocellular carcinoma (HCC). The CAF-derived SPP1 was identified as a candidate molecule driving TKI resistance, and inhibitors of SPP1 can reverse this resistance. Additionally, the plasma level of SPP1 before TKI treatment can serve as a potential biomarker for predicting treatment response in advanced HCC patients.

CANCER COMMUNICATIONS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC

Kevin Zhou et al.

MOLECULAR CANCER (2022)

Add to Collection

Article Engineering, Biomedical

CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment

Yuehua Wang et al.

Summary: By constructing a multi-functional oxygen delivery nanoplatform PFH@LSLP, which can simultaneously deliver sorafenib and CSF1/CSF1R inhibitor PLX3397, this study aims to overcome sorafenib resistance in HCC. The nanoplatform exhibits synergistic effects of hypoxia attenuation, resistance-related gene regulation, and immune-microenvironment modification, showing promising antitumor performance.

BIOACTIVE MATERIALS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Intratumoral stem-like CCR4+regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B

Yanan Gao et al.

Summary: CCR4(+) Tregs play a critical role in hepatitis B-associated hepatocellular carcinoma, contributing to immunotherapy resistance and T cell suppression. Targeting CCR4(+) Tregs can help overcome sorafenib resistance and enhance antitumor immunity by inhibiting their accumulation in the tumor microenvironment and disrupting their stem-like properties.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Review Oncology

Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations

Anthony C. Bejjani et al.

Summary: The treatment landscape for advanced hepatocellular carcinoma has undergone significant changes in recent years, with the introduction of immunotherapy and the development of various treatment regimens. Some combination therapies have shown promising results in improving outcomes for patients. However, there are still knowledge gaps in this rapidly evolving field. It is important for clinicians to stay informed about the safety and efficacy of these evolving regimens to optimize patient outcomes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Hepatocellular carcinoma

Arndt Vogel et al.

Summary: Hepatocellular carcinoma is a common cancer worldwide, with non-alcoholic fatty liver disease becoming a dominant cause. Treatment options are varied, including surgery, radiation, and medication. With the approval of new drugs and the development of immunotherapy, the outlook for hepatocellular carcinoma patients has improved, but the optimal sequencing of drugs and predictive biomarkers still need further research.

LANCET (2022)

Add to Collection

Review Oncology

Tumor-associated macrophages in liver cancer: From mechanisms to therapy

Kun Cheng et al.

Summary: This review discusses the interactions between TAMs and liver cancer cells, the latest therapeutic strategies, and the importance of clinical trials for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), providing a rationale for further investigation of TAMs as a potential target for treating patients with liver cancer.

CANCER COMMUNICATIONS (2022)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Multidisciplinary Sciences

RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-β2

Xia Wang et al.

Summary: Studies have shown that RALYL, a liver progenitor specific gene, regulates HCC stemness by sustaining TGF-beta 2 mRNA stability, which may inspire precise therapeutic strategies for HCC.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Tumor microenvironment as a therapeutic target in cancer

Yi Xiao et al.

Summary: This article summarizes the current progress in targeting the tumor microenvironment in both drug development and clinical trials, emphasizing the challenges in intervening in the tumor microenvironment and discussing strategies to maximize therapeutic benefits. New technologies and approaches to better understand the tumor microenvironment are explored in this context.

PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Review Gastroenterology & Hepatology

Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications

Terence Kin-Wah Lee et al.

Summary: Hepatocellular carcinoma (HCC) is an aggressive disease with poor prognosis, powered by a subset of cancer stem cells (CSCs). Research on liver CSCs has revealed their heterogeneity and unique immunobiology, suggesting potential for new research directions and therapies for HCC.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Review Oncology

Linking EMT programmes to normal and neoplastic epithelial stem cells

Arthur W. Lambert et al.

Summary: Epithelial stem cells play critical roles in tissue generation, maintenance, and repair, while cancer stem cells are implicated in the growth and recurrence of many carcinomas. The activation of epithelial-mesenchymal transition (EMT) is linked to the formation of both normal and neoplastic stem cells, but the mechanistic basis of this connection remains unclear. Understanding the elusive links between EMT programs and the stem cell state will advance our knowledge of normal stem cell biology and cancer pathogenesis.

NATURE REVIEWS CANCER (2021)

Add to Collection

Review Immunology

Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

Kyohei Nakamura et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

Add to Collection

Review Oncology

Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update

Joseph A. Clara et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Intratumoral heterogeneity and clonal evolution in liver cancer

Bojan Losic et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Medicine, General & Internal

The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma

Shunjie Xia et al.

EBIOMEDICINE (2020)

Add to Collection

Article Oncology

Cancer-associated fibroblasts enhance the chemoresistance of CD73(+) hepatocellular carcinoma cancer cells via HGF-Met-ERK1/2 pathway

Hao Peng et al.

ANNALS OF TRANSLATIONAL MEDICINE (2020)

Add to Collection

Review Cell Biology

EMT, MET, Plasticity, and Tumor Metastasis

Basil Bakir et al.

TRENDS IN CELL BIOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells

Gui-Li Xu et al.

GASTROENTEROLOGY REPORT (2020)

Add to Collection

Review Biochemistry & Molecular Biology

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects

Weiwei Tang et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting cancer stem cell pathways for cancer therapy

Liqun Yang et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection

Article Oncology

M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma

Ningning Dong et al.

BRITISH JOURNAL OF CANCER (2019)

Add to Collection

Review Medicine, General & Internal

Hepatocellular Carcinoma

Augusto Villanueva

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Gastroenterology & Hepatology

Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas

Qi Zhang et al.

GUT (2019)

Add to Collection

Article Oncology

Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and sternness-related subpopulations in liver cancer

Daniel Wai-Hung Ho et al.

CANCER LETTERS (2019)

Add to Collection

Article Oncology

HIF-1 alpha-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib

Zhen Song et al.

CANCER LETTERS (2019)

Add to Collection

Review Pharmacology & Pharmacy

RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma

Shaw M. Akula et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2019)

Add to Collection

Article Oncology

COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment

Xiao-Feng Dong et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Gastroenterology & Hepatology

Hypoxia-inducible factor-1/interleukin-1 signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment

Jingying Zhang et al.

HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma

Hongping Zheng et al.

HEPATOLOGY (2018)

Add to Collection

Review Medicine, General & Internal

Hepatocellular carcinoma

Alejandro Forner et al.

LANCET (2018)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Controlled Trials with Meta-Analysis and Trial Sequential Analysis

Xiao-Lin Xu et al.

RADIOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Identification of the tumour transition states occurring during EMT

Ievgenia Pastushenko et al.

NATURE (2018)

Add to Collection

Article Biotechnology & Applied Microbiology

Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress Sorafenib resistance in hepatocellular carcinoma

Hongdan Li et al.

JOURNAL OF NANOBIOTECHNOLOGY (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors

Carolina Mendez-Blanco et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2018)

Add to Collection

Review Gastroenterology & Hepatology

Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation

Tetsuya Ikemoto et al.

HEPATOLOGY RESEARCH (2017)

Add to Collection

Article Oncology

Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells

Yeonhwa Song et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Cell Biology

Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals

Junjie Xu et al.

CELL DEATH & DISEASE (2017)

Add to Collection

Article Oncology

Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells

Zhixin Liu et al.

CANCER LETTERS (2017)

Add to Collection

Article Gastroenterology & Hepatology

Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib

Shao-Lai Zhou et al.

GASTROENTEROLOGY (2016)

Add to Collection

Article Oncology

Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro

Zhen Qu et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)

Add to Collection

Article Gastroenterology & Hepatology

ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α

Fu-Quan Wu et al.

JOURNAL OF HEPATOLOGY (2016)

Add to Collection

Review Gastroenterology & Hepatology

Cancer-associated fibroblasts in hepatocellular carcinoma

Norio Kubo et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2016)

Add to Collection

Review Oncology

Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma

Jiang Chen et al.

CANCER LETTERS (2015)

Add to Collection

Article Gastroenterology & Hepatology

CXCR4 Inhibition in Tumor Microenvironment Facilitates Anti-Programmed Death Receptor-1 Immunotherapy in Sorafenib-Treated Hepatocellular Carcinoma in Mice

Yunching Chen et al.

HEPATOLOGY (2015)

Add to Collection

Article Oncology

Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma

Guohua Lou et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)

Add to Collection

Article Oncology

Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma

Qing-Min Fan et al.

CANCER LETTERS (2014)

Add to Collection

Article Cell Biology

Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells

Dali Zhao et al.

CELLULAR SIGNALLING (2014)

Add to Collection

Article Gastroenterology & Hepatology

Differential Effects of Sorafenib on Liver Versus Tumor Fibrosis Mediated by Stromal-Derived Factor 1 Alpha/C-X-C Receptor Type 4 Axis and Myeloid Differentiation Antigen-Positive Myeloid Cell Infiltration in Mice

Yunching Chen et al.

HEPATOLOGY (2014)

Add to Collection

Article Oncology

Involvement of Extracellular Vesicle Long Noncoding RNA (linc-VLDLR) in Tumor Cell Responses to Chemotherapy

Kenji Takahashi et al.

MOLECULAR CANCER RESEARCH (2014)

Add to Collection

Article Multidisciplinary Sciences

MiR-338-3p Inhibits Hepatocarcinoma Cells and Sensitizes These Cells to Sorafenib by Targeting Hypoxia-Induced Factor 1α

Haitao Xu et al.

PLOS ONE (2014)

Add to Collection

Article Gastroenterology & Hepatology

Hypoxia-Mediated Sorafenib Resistance Can Be Overcome by EF24 Through Von Hippel-Lindau Tumor Suppressor-Dependent HIF-1α Inhibition in Hepatocellular Carcinoma

Yingjian Liang et al.

HEPATOLOGY (2013)

Add to Collection

Article Multidisciplinary Sciences

The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance

Ariel Ka-Man Chow et al.

PLOS ONE (2013)

Add to Collection

Article Oncology

Sorafenib Inhibits Hypoxia-Inducible Factor-1α Synthesis: Implications for Antiangiogenic Activity in Hepatocellular Carcinoma

Li-ping Liu et al.

CLINICAL CANCER RESEARCH (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.